In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best of the Blog: IN VIVO, October 2009

Executive Summary

Our favorite posts from The IN VIVO Blog about issues not covered elsewhere in this month's IN VIVO. (See the original postings for free at

You may also be interested in...

Pricing Experiments: Pharmas Get Creative in Germany

As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. The evolution of these payor-pharma deals in Germany should inform reimbursement strategies elsewhere--including in the US where similar trends are starting to emerge.

The Cost-Sharing Solution: The New NICE Ticket

J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim?

Niche, Lackluster: Summing Up 2008 NCE Launches

The year 2008 won't go down as the bleakest for new chemical entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior. But the NCEs that hit the market were in niche categories or crowded markets, and did little to energize flagging pharmaceutical sales. Take a look back at 2008 drug launches and fears that the traditional blockbuster is dead seem well founded. This article first appeared in The Pink Sheet on January 12, 2009.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts